Literature DB >> 2144016

Protection of mice against yellow fever virus encephalitis by immunization with a vaccinia virus recombinant encoding the yellow fever virus non-structural proteins, NS1, NS2a and NS2b.

J R Putnak1, J J Schlesinger.   

Abstract

Recent evidence of a protective immune response to the flavivirus non-structural protein, NS1, has suggested its incorporation into possible recombinant vaccines. The region of the 17D yellow fever virus (YFV) genome encoding the C terminus of envelope glycoprotein and extending to the N terminus of non-structural protein NS3 (NS1-NS2a-NS2b; nucleotides 2030 to 4940) was expressed in vaccinia virus and physical and immunogenic properties of the NS1 moiety were studied. Recombinant NS1 protein, and native YFV NS1, was detected at the surface of infected cells by immunofluorescence and by immune cytolysis after treatment with anti-NS1 antibody and complement. NS1 was also detected in the extracellular medium as a secreted form. Recombinant NS1 was immunoprecipitated as a single protein of approximately the same size as native 17D YFV NS1. Unboiled, both recombinant and native NS1 formed polymers of high Mr. Immunization of mice with this recombinant vaccinia virus stimulated production of non-neutralizing, complement-fixing cytolytic antibody and conferred partial protection against lethal intracerebral inoculation of mice with live 17D YFV.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2144016     DOI: 10.1099/0022-1317-71-8-1697

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  19 in total

1.  Sequence of the NS 1 gene of the K 23 isolate of tick-borne encephalitis virus and identification of conserved motifs.

Authors:  S C Jacobs; J R Stephenson; G W Wilkinson
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

2.  Meta-analysis of all immune epitope data in the Flavivirus genus: inventory of current immune epitope data status in the context of virus immunity and immunopathology.

Authors:  Kerrie Vaughan; Jason Greenbaum; Martin Blythe; Bjoern Peters; Alessandro Sette
Journal:  Viral Immunol       Date:  2010-06       Impact factor: 2.257

3.  CD8+ T cells complement antibodies in protecting against yellow fever virus.

Authors:  Maria R Bassi; Michael Kongsgaard; Maria A Steffensen; Christina Fenger; Michael Rasmussen; Karsten Skjødt; Bente Finsen; Anette Stryhn; Søren Buus; Jan P Christensen; Allan R Thomsen
Journal:  J Immunol       Date:  2014-12-24       Impact factor: 5.422

4.  Protective role of antigenic sites on the envelope protein of Hantaan virus defined by monoclonal antibodies.

Authors:  J Arikawa; J S Yao; K Yoshimatsu; I Takashima; N Hashimoto
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

5.  The live vector approach-viruses.

Authors:  M Mackett
Journal:  World J Microbiol Biotechnol       Date:  1991-03       Impact factor: 3.312

6.  High-level expression of the tick-borne encephalitis virus NS1 protein by using an adenovirus-based vector: protection elicited in a murine model.

Authors:  S C Jacobs; J R Stephenson; G W Wilkinson
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

Review 7.  Vaccination of adults against travel-related infectious diseases, and new developments in vaccines.

Authors:  P C Döller
Journal:  Infection       Date:  1993 Jan-Feb       Impact factor: 3.553

Review 8.  Progress on the development of therapeutics against West Nile virus.

Authors:  Michael S Diamond
Journal:  Antiviral Res       Date:  2009-06-06       Impact factor: 5.970

9.  Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice.

Authors:  Michael J Engle; Michael S Diamond
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

Review 10.  Flavivirus NS1 and Its Potential in Vaccine Development.

Authors:  Kassandra L Carpio; Alan D T Barrett
Journal:  Vaccines (Basel)       Date:  2021-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.